Recent Transactions

15-Dec-19
$45.4 billion
Target: 

Nutrition & Biosciences Division of DuPont de Nemours, Inc.

United States flag
Acquiror: 
International Flavors and Fragrances, Inc.

Advising IFF, a global leader in flavors and fragrances, on its merger with DuPont’s Nutrition & Biosciences Division, creating a clear global leader in the specialty ingredients sector

27-Jul-15
$40.5 billion
Ireland flag
Target: 

Allergan Generics

Israel flag
Acquiror: 
Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

30-Mar-07
$24.4 billion
United Kingdom flag
Target: 

Alliance Boots plc

United States flag
Acquiror: 
Kohlberg Kravis Roberts & Co. Ltd. and Stefano Pessina

Advised Alliance Boots plc, the leading international pharmacy-led health and beauty group, on a proposal regarding an offer for the company from a consortium comprising of Kohlberg Kravis Roberts & Co. Ltd. and Stefano Pessina

15-Dec-06
$19.1 billion
United Kingdom flag
Target: 

Gallaher Group plc

Japan flag
Acquiror: 
Japan Tobacco Inc.

Advised Gallaher Group plc, the world’s fifth largest tobacco company, on a recommended cash offer from Japan Tobacco Inc

27-Mar-18
$13.0 billion
Switzerland flag
Target: 

Novartis AG’s 36.5% stake in Consumer Health Joint Venture

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

27-Jun-14
$11 billion+
United Kingdom flag
Target: 

TUI Travel Plc

Germany flag
Acquiror: 
TUI AG

Advised TUI AG on the merger with TUI Travel Plc creating the world’s number one integrated leisure tourism business (+Transaction value represents enterprise value of combined entity)

09-Mar-20
$10.6 billion
United Kingdom flag
Target: 

Tesco plc’s Thailand and Malaysia businesses

Thailand flag
Acquiror: 
Charoen Pokphand Group

Advised Tesco plc, a leading UK retailer, on the sale of its Thailand and Malaysia businesses to Charoen Pokphand Group, the Thai conglomerate 

20-May-13
$8.5 billion
Ireland flag
Target: 

Warner Chilcott, plc

United States flag
Acquiror: 
Actavis, Inc.

Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc

06-Jun-14
$7.2 billion
United Kingdom flag
Target: 

AA Limited

flag not available

Advised the management buy-in team on the acquisition by leading institutional investors of AA Limited from Acromas and simultaneous listing on the London Stock Exchange

07-May-18
$7.1 billion
Israel flag
Target: 

Frutarom

United States flag
Acquiror: 
International Flavors and Fragrances

Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition

24-Jul-15
$5.6 billion
United Kingdom flag
Target: 

Gala Coral Limited

United Kingdom flag
Acquiror: 
Ladbrokes plc

Advised Ladbrokes plc, a leading UK betting and gaming company, on the recommended all-share merger with certain businesses of Gala Coral Limited, including Coral Retail, Eurobet Retail and Gala Coral Online

22-Dec-17
$5.3 billion
United Kingdom flag
Target: 

Ladbrokes Coral Group PLC

United Kingdom flag
Acquiror: 
GVC Holdings PLC

Advised Ladbrokes Coral Group PLC, a leading multi-channel sports betting and gaming company, on a recommended offer from GVC Holdings PLC, a multi-national online sports betting and gaming company

27-Jan-17
$4.6 billion
United Kingdom flag
Target: 

Booker Group plc

United Kingdom flag
Acquiror: 
Tesco plc

Advised Tesco plc, the UK’s leading retailer, on its merger with Booker Group plc, the UK’s leading food wholesaler, to create the UK’s leading food business

03-Dec-18
$4.0 billion
United Kingdom flag
Target: 

Assets owned by GlaxoSmithKline plc

Acquiror: 
Unilever plc / Hindustan Unilever Limited

Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited

10-Jun-20
$3.9 billion
Denmark flag
Target: 

Global collaboration agreement with Genmab A/S

United States flag
Acquiror: 
AbbVie, Inc

Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs  

04-Jun-07
$2.9 billion
U.S.A., U.K. flags
Target: 

Slough Estates USA (subsidiary of Slough Estates plc)

United States flag
Acquiror: 
Health Care Property Investors

Provided oversight of the process and an informal second opinion to the senior management of Slough Estates plc

09-Sep-13
$2.1 billion
United Kingdom flag
Target: 

Lucozade & Ribena brands (owned by GSK)

Japan flag
Acquiror: 
Suntory Beverage & Food Ltd

Advised GlaxoSmithKline, the UK listed international pharmaceutical and consumer company, on the sale of its nutritional drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd

28-Jul-08
$2.1 billion
United Kingdom flag
Target: 

Tesco Personal Finance Group Limited

United Kingdom flag
Acquiror: 
Tesco plc

Advised Tesco plc in relation to its acquisition of the 50% interest it does not already own in Tesco Personal Finance Group Limited, a joint venture with The Royal Bank of Scotland Group plc. Tesco Personal Finance offers a range of retail insurance and banking products under the Tesco brand

30-Jun-11
$1.7 billion
United Kingdom flag
Target: 

Minerva plc

United Kingdom flag
Acquiror: 
Jupiter Properties (owned by AREA Property Partners and Delancey Real Estate Asset Mgmt)

Advised Minerva plc, a property investment and development company, on a recommended offer from a consortium consisting of AREA Property Partners and Delancey Real Estate Asset Management

28-Jul-22
Pending
$1.6 billion
Chile Flag
Target: 

Derco Holdings

United Kingdom flag
Acquiror: 
Inchcape Plc

Advising and acting as sponsor to Inchcape plc, the leading independent global automotive distributor, on its proposed Class 1 acquisition of Derco, the largest independent automotive distributor by volume in Latin America

22-Feb-19
$1.6 billion
United Kingdom flag
Target: 

Dairy Crest Group plc

Canada flag
Acquiror: 
Saputo Inc.

Advised Dairy Crest Group plc, a producer of leading British food brands and value-added ingredients, on a recommended cash offer for its entire issued share capital from Saputo Inc, one of the top ten dairy processors in the world

28-Mar-22
Pending
~$1.4 billion
United Kingdom flag
Target: 

Theramex

United States flag
Acquiror: 
Carlyle and PAI Partners

Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners

15-Oct-18
$1.1 billion
U.K., Ireland flags
Target: 

Greencore Group plc’s US business

United States flag
Acquiror: 
Hearthside Food Solutions LLC

Advised and acted as sponsor to Greencore Group plc, a leading international manufacturer of convenience foods based in Ireland, on the disposal of its entire US business to Hearthside Foods Solutions

16-May-16
$874 million
U.K., Netherlands, Germany flags
Target: 

Equinix Data Center Assets

United States flag
Acquiror: 
Digital Realty Trust

Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix

05-Oct-16
$775 million
U.K., Ireland flags
Target: 

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m) 

Pages

show all